Recruiting

Patient CommunicationAsk Questions About Clinical Trials

Sponsor:

Barbara Ann Karmanos Cancer Institute

Code:

NCT07343297

Conditions

Oncology

Cardiac Disease

Neurologic Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ask Questions about Clinical Trials brochure

Study Details

Brief summary:

The overall goal of this study is to assess the implementation of the Ask Questions about Clinical Trials (ASQ-CT) brochure, a patient-focused communication tool previously demonstrated to improve patient-provider communication about clinical trials. Participants will be given the ASQ-CT brochure at Time 1 (baseline) and participants will complete a questionnaire at three timepoints, baseline (Time 1), Pre-Research Visit (Time 2), and Post-Research Visit (Time 3).

Conditions

Oncology

Cardiac Disease

Neurologic Disorder

Study ID

NCT07343297

Start date

Dec 30, 2026

Status verified date

Jun, 2026

Completion date

Apr 5, 2028

Anticipated

Primary completion date

Dec 30, 2027

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Age > or equal to 18 years
Appointment to see a provider at a Karmanos Cancer Institute-McLaren or a medical encounter at McLaren Center for Research and Innovation (MCRI) site for medical/systemic treatment
Potentially eligible for a clinical trial
Speak and read English well enough to be able to understand consent documents and complete surveys

Exclusion Criteria:

Not able to complete study documents on their own physically or cognitively

Study Design

Enrollment

293 participants

Anticipated

Intervention Model

Single group

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

experimental: Ask Questions about Clinical Trials (ASQ-CT) Brochure

Ask Questions about Clinical Trials (ASQ-CT), a clinical trial communication intervention brochure

Interventions

Ask Questions about Clinical Trials brochure

Communication intervention called a question prompt list

Primary outcome measure

Effectiveness - Self-Efficacy in managing patient-provider interactions - Quantitative Scale [ Time Frame: From Baseline (Time 1) to end of Pre-Clinic Visit (Time 2) ]

Central Contacts and Locations

Central contacts

Lauren M Hamel, PhD, MBA

1-800-527-6266 Lauren.Hamel@med.wayne.edu

Locations

Karmanos Cancer Institute at McLaren Bay Region

Recruiting

Bay City, Michigan, United States, 48706

Contacts

989-667-2370

Karmanos Cancer Institute at McLaren Clarkston

Recruiting

Clarkston, Michigan, United States, 48346

Contacts

248-922-6650

Karmanos Cancer Institute at McLaren Greater Lansing

Recruiting

Lansing, Michigan, United States, 48910

Contacts

517-975-9500

Karmanos Cancer Institute at McLaren Lapeer

Recruiting

Lapeer, Michigan, United States, 48446

Contacts

810-667-4994

Karmanos Cancer Institute at McLaren Macomb

Recruiting

Mount Clemens, Michigan, United States, 48043

Contacts

586-493-7510

Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center

Recruiting

Mount Pleasant, Michigan, United States, 48858

Contacts

989-772-6811

Karmanos Cancer Institute at McLaren Northern Michigan

Recruiting

Petoskey, Michigan, United States, 49770

Contacts

231-487-4209

Karmanos Cancer Institute at McLaren Port Huron

Recruiting

Port Huron, Michigan, United States, 48060

Contacts

810-982-5200

More Information

Sponsor

Barbara Ann Karmanos Cancer Institute

Last update posted

Aug 6, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Barbara Ann Karmanos Cancer Institute on 2026-08-06.